Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy: A Prospective, Randomized, Controlled, Multicenter Clinical Study

What this Trial Is About

This research aims to evaluate the efficacy and safety of finerenone in patients with primary membranous nephropathy (PMN), a kidney condition. The trial is a prospective, randomized, controlled, multicenter study involving 116 patients. It compares the effects of adding finerenone to the current treatment of maximum tolerated doses of ACE inhibitors (ACEI) or angiotensin receptor blockers (ARB) against ACEI/ARB treatment alone. The primary goal is to measure the change in urinary protein levels over six months. Participants will first receive at least four weeks of maximum tolerated ACEI/ARB therapy. Then, they will be randomly assigned to either continue ACEI/ARB alone or receive ACEI/ARB plus finerenone 20 mg once daily. The study compares these two groups over a 24-week period, focusing on how their urinary protein content changes. The design includes no masking or blinding and uses random allocation to study groups. During the study, participants will undergo regular assessments including urine tests to measure protein levels, blood pressure monitoring, and kidney function tests such as estimated glomerular filtration rate (eGFR). Researchers will track changes from baseline to 24 weeks to evaluate treatment effects. The total participation time spans from initial treatment through six months of follow-up, with safety and adherence monitored throughout the study.

Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy